[go: up one dir, main page]

AR116036A1 - DERIVADOS DE NAFTIRIDINA COMO INHIBIDORES DE INTEGRINA avb6 - Google Patents

DERIVADOS DE NAFTIRIDINA COMO INHIBIDORES DE INTEGRINA avb6

Info

Publication number
AR116036A1
AR116036A1 ARP190102463A ARP190102463A AR116036A1 AR 116036 A1 AR116036 A1 AR 116036A1 AR P190102463 A ARP190102463 A AR P190102463A AR P190102463 A ARP190102463 A AR P190102463A AR 116036 A1 AR116036 A1 AR 116036A1
Authority
AR
Argentina
Prior art keywords
alkylene
alkyl
compound
formula
alkoxy
Prior art date
Application number
ARP190102463A
Other languages
English (en)
Inventor
Byungchan Kim
Tyler Day
Kyle D Konze
Eugene Hickey
Mats A Svensson
Andrea Bortolato
Aleksey I Gerasyuto
Brian Sosa
Fu Lin
- Zhong Cheng Yang
Bruce N Rogers
Blaise S Lippa
Dawn M Troast
Matthew G Bursavich
James E Dowling
Bryce A Harrison
Original Assignee
Morphic Therapeutic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphic Therapeutic Inc filed Critical Morphic Therapeutic Inc
Publication of AR116036A1 publication Critical patent/AR116036A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se proveen derivados de 1,2,3,4-tetrahidro-1,8-naftiridina como inhibidores de integrina avb6 y composiciones farmacéuticas que los comprenden. Reivindicación 1: Un compuesto de fórmula (1): A-B-C (1) caracterizado porque: A es un compuesto de fórmula (2) ó (3); B es -alquilen-C*H(F)-, -alquilen-C*(F)₂-, -alquilen-CH(F)C*H₂-, -alquilen-C(F)₂C*H₂-, -alquilen-O-alquilen-C*H(F)-, o -alquilen-O-alquilen-C*(F)₂-; C es un compuesto de fórmula (4); R¹ es independiente de H, alquilo, haluro, alcoxi, CF₃, OH, alquilen-OH, NO₂ o -N(H)Rᵃ; R² es H, alquilo, arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, cicloalquilo, -alquilen-alcoxi, alquilen-arilo, o heterocicloalquilo; R³ se selecciona independientemente entre H, haluro, CF₃, alquilo, alquilen-alcoxi, arilo, hidroxilo y alcoxi; Rᵃ es H, C₁₋₆ alquilo, -C₁₋₆ alquilen-O-C₁₋₆ alquilo, o -C₁₋₆ alquilen-O-C(O)OC₁₋₆ alquilo; n es 0, 1, 2, 3, ó 4; * denota el punto de unión de B a C; y la configuración absoluta en cualquier estereocentro es R, S, o una mezcla de las mismas; o una sal aceptable farmacéuticamente del mismo. Reivindicación 45: Un compuesto de fórmula (1): A-B-C (1) caracterizado porque: A es un compuesto de fórmula (2) ó (3); B es -alquilen-C*H(F)-, -alquilen-C*(F)₂-, -alquilen-CH(F)C*H₂-, -alquilen-C(F)₂C*H₂-; C es un compuesto de fórmula (4); R¹ es independiente de H, alquilo, haluro, alcoxi, CF₃, OH, alquilen-OH, NO₂ o -N(H)Rᵃ; R² es arilo sustituido o no sustituido, heteroarilo sustituido o no sustituido, cicloalquilo, alquilen-arilo, o heterocicloalquilo; Rᵃ es H; n es 0; * denota el punto de unión de B a C; y la configuración absoluta en cualquier estereocentro es R, S, o una mezcla de las mismas; o una sal aceptable farmacéuticamente del mismo.
ARP190102463A 2018-08-29 2019-08-29 DERIVADOS DE NAFTIRIDINA COMO INHIBIDORES DE INTEGRINA avb6 AR116036A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862724397P 2018-08-29 2018-08-29

Publications (1)

Publication Number Publication Date
AR116036A1 true AR116036A1 (es) 2021-03-25

Family

ID=70284760

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190102463A AR116036A1 (es) 2018-08-29 2019-08-29 DERIVADOS DE NAFTIRIDINA COMO INHIBIDORES DE INTEGRINA avb6

Country Status (17)

Country Link
US (1) US12528803B2 (es)
EP (1) EP3844162B1 (es)
AR (1) AR116036A1 (es)
DK (1) DK3844162T3 (es)
ES (1) ES3018512T3 (es)
FI (1) FI3844162T3 (es)
HR (1) HRP20250289T1 (es)
HU (1) HUE071053T2 (es)
LT (1) LT3844162T (es)
PL (1) PL3844162T3 (es)
PT (1) PT3844162T (es)
RS (1) RS66733B1 (es)
SI (1) SI3844162T1 (es)
SM (1) SMT202500129T1 (es)
TW (3) TWI857918B (es)
UY (1) UY38352A (es)
WO (1) WO2020081154A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102891803B1 (ko) 2017-02-28 2025-11-28 모픽 테라퓨틱, 인코포레이티드 αvβ6 인테그린 억제제
EP3760202A1 (en) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
UY38352A (es) 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibidores de integrina alfavbeta6
JP7540998B2 (ja) 2018-08-29 2024-08-27 モーフィック セラピューティック，インコーポレイテッド αｖβ６インテグリンの阻害
WO2024173570A1 (en) * 2023-02-14 2024-08-22 Morphic Therapeutic, Inc. INHIBITING αvβ8 INTEGRIN

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH07501063A (ja) 1991-11-14 1995-02-02 グラクソ、グループ、リミテッド フィブリノーゲン依存性血小板凝集阻害剤としてのピペリジン酢酸誘導体
AU3351293A (en) 1992-01-21 1993-08-03 Glaxo Group Limited Piperidineacetic acid derivatives as inhibitors of fibrinogen-dependent blood platelet aggregation
ATE181735T1 (de) 1993-05-01 1999-07-15 Merck Patent Gmbh Substituierte 1-phenyl-oxazolidin-2-on derivate, deren herstellung und deren verwendung als adhäsionsrezeptor-antagonisten
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
CN1209063A (zh) 1995-12-29 1999-02-24 史密丝克莱恩比彻姆公司 玻连蛋白受体拮抗剂
BR9612378A (pt) 1995-12-29 1999-07-13 Smithkline Beecham Corp Antagonistas receptores de vitronectina
US20010034445A1 (en) 1995-12-29 2001-10-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1997026250A1 (en) 1996-01-16 1997-07-24 Merck & Co., Inc. Integrin receptor antagonists
ATE212990T1 (de) 1996-03-20 2002-02-15 Hoechst Ag Inhibitoren der knochenresorption und vitronectinrezeptor-antagonisten
ES2214604T3 (es) 1996-03-29 2004-09-16 Pfizer Inc. Derivados de la 6-fenilpiridil-2-amina.
WO1998008840A1 (en) 1996-08-29 1998-03-05 Merck & Co., Inc. Integrin antagonists
US5952341A (en) 1996-10-30 1999-09-14 Merck & Co., Inc. Integrin antagonists
AU722360B2 (en) 1996-10-30 2000-08-03 Merck & Co., Inc. Integrin antagonists
EP0973396A4 (en) 1997-04-07 2001-02-07 Merck & Co Inc METHOD FOR TREATING CANCER
WO1998046220A1 (en) 1997-04-14 1998-10-22 Merck & Co., Inc. Combination therapy for the prevention and treatment of osteoporosis
WO1999026945A1 (en) 1997-11-26 1999-06-03 Du Pont Pharmaceuticals Company 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS αvβ3 ANTAGONISTS
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
ATE294163T1 (de) * 1997-12-17 2005-05-15 Merck & Co Inc Integrin-rezeptor-antagonisten
JP3589633B2 (ja) 1997-12-17 2004-11-17 メルク エンド カムパニー インコーポレーテッド インテグリン受容体拮抗薬
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
DE69830806T2 (de) 1997-12-17 2006-04-27 Merck & Co., Inc. Integrinrezeptor antagonisten
AU736026B2 (en) 1997-12-17 2001-07-26 Merck & Co., Inc. Integrin receptor antagonists
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
AU747784B2 (en) 1998-07-29 2002-05-23 Merck & Co., Inc. Integrin receptor antagonists
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
BR9916323A (pt) 1998-12-19 2001-10-30 Merck Patent Gmbh Inibidores da integrina alfavbeta6
EP1150965A4 (en) 1999-02-03 2002-05-15 Merck & Co Inc BENZAZEPINE DERIVATIVES AS ALPHA-V INTGRIN RECEPTOR ANTAGONISTS
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
DE60035779T2 (de) 1999-06-02 2008-04-30 Merck & Co., Inc. Alpha v integrin-rezeptor antagonisten
EP1194151A4 (en) 1999-06-23 2003-01-15 Merck & Co Inc ANTAGONISTS OF THE INTEGRIN RECEPTORS
DE19933173A1 (de) 1999-07-15 2001-01-18 Merck Patent Gmbh Cyclische Peptidderivate als Inhibitoren des Integrins alpha¶v¶beta¶6¶
US6514964B1 (en) 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
GB9929988D0 (en) 1999-12-17 2000-02-09 Celltech Therapeutics Ltd Chemical compounds
EP1252162B1 (en) 2000-01-20 2012-07-25 Merck Sharp & Dohme Corp. Alpha v integrin receptor antagonists
EP1254116A4 (en) 2000-01-24 2003-04-23 Merck & Co Inc ALPHA V INTEGRIN RECEPTOR ANTAGONISTS
US7119098B2 (en) 2000-06-15 2006-10-10 Pharmacia Corporation Heteroarylakanoic acids as intergrin receptor antagonists
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
JP2004509123A (ja) 2000-09-14 2004-03-25 メルク　エンド　カムパニー　インコーポレーテッド アルファνインテグリン受容体アンタゴニスト
WO2002022616A2 (en) 2000-09-14 2002-03-21 Merck & Co., Inc. Alpha v integrin receptor antagonists
US20050004199A1 (en) 2000-09-18 2005-01-06 George Hartman Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist
WO2002060438A1 (en) 2001-01-29 2002-08-08 3-Dimensional Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
CA2445679A1 (en) 2001-05-03 2002-11-14 Paul J. Coleman Benzazepinone alpha v integrin receptor antagonists
US20040043988A1 (en) 2001-06-15 2004-03-04 Khanna Ish Kurmar Cycloalkyl alkanoic acids as intergrin receptor antagonists
DE10204789A1 (de) 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta6
US20040077684A1 (en) 2002-08-16 2004-04-22 Bart De Corte Piperidinyl compounds that selectively bind integrins
FI20041129A0 (fi) 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
AR059224A1 (es) 2006-01-31 2008-03-19 Jerini Ag Compuestos para la inhibicion de integrinas y uso de estas
EP2049490A1 (en) 2006-06-09 2009-04-22 Astra Zeneca AB N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
TW200848024A (en) 2007-06-13 2008-12-16 Bristol Myers Squibb Co Dipeptide analogs as coagulation factor inhibitors
AU2008321770B2 (en) 2007-11-16 2012-09-06 Ube Industries, Ltd. Benzazepinone compound
US20120289481A1 (en) 2011-05-13 2012-11-15 O'neil Jennifer Compositions and methods for treating cancer
IN2015DN00099A (es) 2012-07-18 2015-05-29 Univ Saint Louis
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
EP2784511A1 (en) 2013-03-27 2014-10-01 Universität Zürich Integrin alpha-v-beta6 for diagnosis/prognosis of colorectal carcinoma
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
WO2015103643A2 (en) 2014-01-06 2015-07-09 The General Hospital Corporation Integrin antagonists
MA39823A (fr) 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
WO2015179823A2 (en) 2014-05-23 2015-11-26 The California Institute For Biomedical Research Lung localized inhibitors of alpha(v)beta 6
WO2016022851A1 (en) 2014-08-06 2016-02-11 Children's Medical Center Corporation Modified integrin polypeptides, modified integrin polypeptide dimers, and uses thereof
GB201417011D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
ES2892954T3 (es) * 2015-02-19 2022-02-07 Ocuterra Therapeutics Inc Derivados fluorados del ácido 3-(2-oxo-3-(3-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)propil)imidazolidin-1-il)propanoico y usos de los mismos
PL3275883T3 (pl) 2015-03-25 2021-11-15 Fujifilm Corporation Sposób wytwarzania nowego związku zawierającego atom azotu lub jego soli oraz związku pośredniego do ich wytwarzania
CN108040467A (zh) 2015-04-30 2018-05-15 赛弗卢尔生命科学公司 四氢萘啶基丙酸衍生物及其用途
CN108779077A (zh) 2015-12-30 2018-11-09 圣路易斯大学 作为pan整合素拮抗剂的间位氮杂环氨基苯甲酸衍生物
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
DE102016003731A1 (de) * 2016-03-24 2017-09-28 Friedrich-Alexander-Universität Erlangen-Nürnberg Verfahren zum Erzeugen eines Kompositmaterials mit hierarchischer Porosität
JP2019524702A (ja) 2016-07-05 2019-09-05 ザ ロックフェラー ユニバーシティー テトラヒドロナフチルリジンペンタンアミドインテグリンアンタゴニスト
TW201823208A (zh) 2016-09-07 2018-07-01 美商普萊恩醫療公司 N－醯基胺基酸化合物及其使用方法
EA201991102A1 (ru) 2016-11-01 2019-09-30 Эрроухед Фармасьютикалс, Инк. Альфа-v бета-6 лиганды интегрина и варианты их применения
WO2018085578A1 (en) 2016-11-02 2018-05-11 Saint Louis University Integrin inhibitors in combination with an agent which interacts with a chemokine receptor
WO2018085552A1 (en) 2016-11-02 2018-05-11 Saint Louis University Integrin antagonists
MX377359B (es) 2016-11-08 2025-03-10 Bristol Myers Squibb Co Compuestos mono y espirocíclicos que continen ciclobutano y azetidina como inhibidores de la integrina alfa v.
BR112019009293A2 (pt) 2016-11-08 2019-07-30 Bristol-Myers Squibb Company pirrol amidas como inibidores de integrina alfa v
MA46745A (fr) 2016-11-08 2021-03-31 Bristol Myers Squibb Co Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
NZ754207A (en) 2016-11-08 2025-09-26 Bristol Myers Squibb Co 3-substituted propionic acids as alpha v integrin inhibitors
EP3538527B1 (en) 2016-11-08 2021-10-13 Bristol-Myers Squibb Company Azole amides and amines as alpha v integrin inhibitors
USRE50554E1 (en) * 2016-12-23 2025-08-26 Pliant Therapeutics, Inc. Amino acid compounds and methods of use
MX2019007797A (es) 2016-12-29 2019-10-21 Univ Saint Louis Antagonistas de integrinas.
KR102891803B1 (ko) 2017-02-28 2025-11-28 모픽 테라퓨틱, 인코포레이티드 αvβ6 인테그린 억제제
EP3760202A1 (en) 2017-02-28 2021-01-06 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
MD3761980T2 (ro) 2018-03-07 2024-09-30 Pliant Therapeutics Inc Compuși de aminoacid și metodele utilizare
TWI841573B (zh) 2018-06-27 2024-05-11 美商普萊恩醫療公司 具有未分支連接子之胺基酸化合物及使用方法
WO2020009889A1 (en) 2018-07-03 2020-01-09 Saint Louis University ALPHAvBETA1 INTEGRIN ANTAGONISTS
JP7540998B2 (ja) 2018-08-29 2024-08-27 モーフィック セラピューティック，インコーポレイテッド αｖβ６インテグリンの阻害
EP3843727A4 (en) 2018-08-29 2022-08-17 Morphic Therapeutic, Inc. INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN
UY38352A (es) 2018-08-29 2020-03-31 Morphic Therapeutic Inc Inhibidores de integrina alfavbeta6
ES3027421T3 (en) 2018-08-29 2025-06-13 Morphic Therapeutic Inc Inhibitors of (alpha-v)(beta-6) integrin
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
US11419869B2 (en) 2019-04-08 2022-08-23 Pliant Therapeutics, Inc. Dosage forms and regimens for amino acid compounds

Also Published As

Publication number Publication date
PL3844162T3 (pl) 2025-06-09
FI3844162T3 (fi) 2025-03-27
SI3844162T1 (sl) 2025-06-30
TWI835840B (zh) 2024-03-21
TW202528309A (zh) 2025-07-16
TWI902445B (zh) 2025-10-21
HUE071053T2 (hu) 2025-07-28
DK3844162T3 (da) 2025-03-03
TWI857918B (zh) 2024-10-01
SMT202500129T1 (it) 2025-05-12
PT3844162T (pt) 2025-03-28
LT3844162T (lt) 2025-05-26
US20230242524A1 (en) 2023-08-03
HRP20250289T1 (hr) 2025-05-09
WO2020081154A1 (en) 2020-04-23
RS66733B1 (sr) 2025-05-30
EP3844162A1 (en) 2021-07-07
EP3844162A4 (en) 2022-05-25
TW202019928A (zh) 2020-06-01
US12528803B2 (en) 2026-01-20
EP3844162B1 (en) 2025-01-01
TW202423925A (zh) 2024-06-16
UY38352A (es) 2020-03-31
ES3018512T3 (es) 2025-05-16

Similar Documents

Publication Publication Date Title
AR116036A1 (es) DERIVADOS DE NAFTIRIDINA COMO INHIBIDORES DE INTEGRINA avb6
DOP2022000039A (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
AR114164A1 (es) Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
PE20230249A1 (es) Compuestos de heteroarilo biciclicos y usos de estos
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
CL2018002410A1 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR102177A1 (es) Compuestos de heteroarilo como inhibidores de btk y usos de los mismos
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
AR076900A1 (es) Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc
MX375978B (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2.
MX420195B (es) Compuestos macrocíclicos como agonistas de sting y métodos y usos de los mismos
ECSP17007208A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
AR083879A1 (es) Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos
CY1124245T1 (el) Τρικυκλικα συγχωνευμενα παραγωγα πυριδινης-2-ενα και η χρηση τους ως αναστολεις brd4
AR090587A1 (es) Compuestos triciclicos sustituidos con actividad hacia los receptores ep1
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
AR075235A1 (es) Derivados de indol como agentes anticancer.
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
AR101395A1 (es) Derivados de indolizina y su uso en enfermedades neurodegenerativas
AR045159A1 (es) Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos
UY36124A (es) Derivados de carboxamida
PE20190964A1 (es) Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica
MX2019006612A (es) Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta (pi3kdelta).
CL2017001720A1 (es) Nuevos derivados de bencimidazol como agentes antihistamínicos.